Early-Stage Device Firms Challenge CV Big Five With Alternatives, Adjuncts
This article was originally published in The Gray Sheet
Executive Summary
Small companies at the research stage are asking investors to support cardiovascular technology projects that would fill treatment gaps left open by surgical interventions and large firms' stent technologies